1914 related articles for article (PubMed ID: 8319494)
1. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
[TBL] [Abstract][Full Text] [Related]
2. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
3. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
Basak S; Birebent B; Purev E; Somasundaram R; Maruyama H; Zaloudik J; Swoboda R; Strittmatter W; Li W; Luckenbach A; Song H; Li J; Sproesser K; Guerry D; Nair S; Furukawa K; Herlyn D
Cancer Immunol Immunother; 2003 Mar; 52(3):145-54. PubMed ID: 12649743
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Yang H; Jager MJ; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
7. Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas.
Săftescu S; Munteanu M; Popovici D; Dragomir R; Negru AG; Pac PC; Negru ȘM
Rom J Ophthalmol; 2020; 64(2):184-189. PubMed ID: 32685785
[TBL] [Abstract][Full Text] [Related]
8. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
Livingston PO; Ritter G; Calves MJ
Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
[TBL] [Abstract][Full Text] [Related]
9. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
Nakamura K; Tanaka Y; Shitara K; Hanai N
Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
[TBL] [Abstract][Full Text] [Related]
10. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
[TBL] [Abstract][Full Text] [Related]
11. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides.
Zhang S; Helling F; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Feb; 40(2):88-94. PubMed ID: 7882387
[TBL] [Abstract][Full Text] [Related]
12. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
13. Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA.
Soman G; Yang X; Jiang H; Giardina S; Mitra G
J Immunol Methods; 2011 Oct; 373(1-2):181-91. PubMed ID: 21893062
[TBL] [Abstract][Full Text] [Related]
14. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD3.
Hersey P; MacDonald M; Burns C; Cheresh DA
Cancer Immunol Immunother; 1987; 24(2):144-50. PubMed ID: 3493846
[TBL] [Abstract][Full Text] [Related]
16. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
Irie RF; Ollila DW; O'Day S; Morton DL
Cancer Immunol Immunother; 2004 Feb; 53(2):110-7. PubMed ID: 14564483
[TBL] [Abstract][Full Text] [Related]
17. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract][Full Text] [Related]
18. Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis.
Richards JR; Shin D; Pryor R; Sorensen LK; Sun Z; So WM; Park G; Wolff R; Truong A; McMahon M; Grossmann AH; Harbour JW; Zhu W; Odelberg SJ; Yoo JH
Oncogene; 2023 Aug; 42(35):2629-2640. PubMed ID: 37500798
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Immune interactions: implications for cancer therapy.
Tham M; Abastado JP
Cell Cycle; 2015; 14(9):1347-8. PubMed ID: 25894850
[No Abstract] [Full Text] [Related]
20. Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas.
Bosslet K; Mennel HD; Rodden F; Bauer BL; Wagner F; Altmannsberger A; Sedlacek HH; Wiegandt H
Cancer Immunol Immunother; 1989; 29(3):171-8. PubMed ID: 2471592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
